vs
Side-by-side financial comparison of CROSS COUNTRY HEALTHCARE INC (CCRN) and HALOZYME THERAPEUTICS, INC. (HALO). Click either name above to swap in a different company.
HALOZYME THERAPEUTICS, INC. is the larger business by last-quarter revenue ($451.8M vs $236.8M, roughly 1.9× CROSS COUNTRY HEALTHCARE INC). HALOZYME THERAPEUTICS, INC. runs the higher net margin — -31.3% vs -35.0%, a 3.7% gap on every dollar of revenue. On growth, HALOZYME THERAPEUTICS, INC. posted the faster year-over-year revenue change (51.6% vs -23.6%). HALOZYME THERAPEUTICS, INC. produced more free cash flow last quarter ($217.6M vs $16.1M). Over the past eight quarters, HALOZYME THERAPEUTICS, INC.'s revenue compounded faster (51.9% CAGR vs -21.0%).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
CCRN vs HALO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $236.8M | $451.8M |
| Net Profit | $-82.9M | $-141.6M |
| Gross Margin | — | 82.6% |
| Operating Margin | -30.2% | -20.6% |
| Net Margin | -35.0% | -31.3% |
| Revenue YoY | -23.6% | 51.6% |
| Net Profit YoY | -2109.7% | -203.3% |
| EPS (diluted) | $-2.56 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $236.8M | $451.8M | ||
| Q3 25 | $250.1M | $354.3M | ||
| Q2 25 | $274.1M | $325.7M | ||
| Q1 25 | $293.4M | $264.9M | ||
| Q4 24 | $309.9M | $298.0M | ||
| Q3 24 | $315.1M | $290.1M | ||
| Q2 24 | $339.8M | $231.4M | ||
| Q1 24 | $379.2M | $195.9M |
| Q4 25 | $-82.9M | $-141.6M | ||
| Q3 25 | $-4.8M | $175.2M | ||
| Q2 25 | $-6.7M | $165.2M | ||
| Q1 25 | $-490.0K | $118.1M | ||
| Q4 24 | $-3.8M | $137.0M | ||
| Q3 24 | $2.6M | $137.0M | ||
| Q2 24 | $-16.1M | $93.2M | ||
| Q1 24 | $2.7M | $76.8M |
| Q4 25 | — | 82.6% | ||
| Q3 25 | 20.4% | 84.4% | ||
| Q2 25 | 20.4% | 85.8% | ||
| Q1 25 | 20.0% | 81.7% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | 20.4% | 83.0% | ||
| Q2 24 | 20.8% | 82.9% | ||
| Q1 24 | 20.4% | 85.5% |
| Q4 25 | -30.2% | -20.6% | ||
| Q3 25 | -2.4% | 61.5% | ||
| Q2 25 | -2.1% | 62.2% | ||
| Q1 25 | -0.3% | 53.4% | ||
| Q4 24 | -1.1% | 58.9% | ||
| Q3 24 | 0.9% | 56.3% | ||
| Q2 24 | -5.7% | 50.7% | ||
| Q1 24 | 0.8% | 48.8% |
| Q4 25 | -35.0% | -31.3% | ||
| Q3 25 | -1.9% | 49.5% | ||
| Q2 25 | -2.4% | 50.7% | ||
| Q1 25 | -0.2% | 44.6% | ||
| Q4 24 | -1.2% | 46.0% | ||
| Q3 24 | 0.8% | 47.2% | ||
| Q2 24 | -4.7% | 40.3% | ||
| Q1 24 | 0.7% | 39.2% |
| Q4 25 | $-2.56 | $-1.13 | ||
| Q3 25 | $-0.15 | $1.43 | ||
| Q2 25 | $-0.20 | $1.33 | ||
| Q1 25 | $-0.02 | $0.93 | ||
| Q4 24 | $-0.13 | $1.06 | ||
| Q3 24 | $0.08 | $1.05 | ||
| Q2 24 | $-0.47 | $0.72 | ||
| Q1 24 | $0.08 | $0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.7M | $133.8M |
| Total DebtLower is stronger | — | $2.1B |
| Stockholders' EquityBook value | $322.8M | $48.8M |
| Total Assets | $449.0M | $2.5B |
| Debt / EquityLower = less leverage | — | 43.89× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.7M | $133.8M | ||
| Q3 25 | $99.1M | $419.7M | ||
| Q2 25 | $81.2M | $61.9M | ||
| Q1 25 | $80.7M | $176.3M | ||
| Q4 24 | $81.6M | $115.8M | ||
| Q3 24 | $64.0M | $154.3M | ||
| Q2 24 | $69.6M | $187.9M | ||
| Q1 24 | $5.2M | $164.6M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
| Q4 25 | $322.8M | $48.8M | ||
| Q3 25 | $408.1M | $503.9M | ||
| Q2 25 | $412.2M | $332.7M | ||
| Q1 25 | $418.2M | $482.3M | ||
| Q4 24 | $419.0M | $363.8M | ||
| Q3 24 | $424.7M | $452.7M | ||
| Q2 24 | $433.3M | $289.4M | ||
| Q1 24 | $462.4M | $177.8M |
| Q4 25 | $449.0M | $2.5B | ||
| Q3 25 | $538.2M | $2.2B | ||
| Q2 25 | $553.8M | $2.1B | ||
| Q1 25 | $576.2M | $2.2B | ||
| Q4 24 | $589.3M | $2.1B | ||
| Q3 24 | $597.4M | $2.1B | ||
| Q2 24 | $602.9M | $2.0B | ||
| Q1 24 | $648.4M | $1.8B |
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× | ||
| Q1 24 | — | 8.44× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.2M | $219.0M |
| Free Cash FlowOCF − Capex | $16.1M | $217.6M |
| FCF MarginFCF / Revenue | 6.8% | 48.2% |
| Capex IntensityCapex / Revenue | 0.9% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | $644.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $219.0M | ||
| Q3 25 | $20.1M | $178.6M | ||
| Q2 25 | $4.2M | $99.7M | ||
| Q1 25 | $5.7M | $154.2M | ||
| Q4 24 | $24.2M | $178.5M | ||
| Q3 24 | $7.5M | $115.4M | ||
| Q2 24 | $82.4M | $55.8M | ||
| Q1 24 | $6.0M | $129.4M |
| Q4 25 | $16.1M | $217.6M | ||
| Q3 25 | $17.9M | $175.6M | ||
| Q2 25 | $2.3M | $98.1M | ||
| Q1 25 | $3.8M | $153.3M | ||
| Q4 24 | $21.7M | $175.4M | ||
| Q3 24 | $6.3M | $113.9M | ||
| Q2 24 | $79.6M | $53.2M | ||
| Q1 24 | $3.8M | $125.9M |
| Q4 25 | 6.8% | 48.2% | ||
| Q3 25 | 7.2% | 49.6% | ||
| Q2 25 | 0.8% | 30.1% | ||
| Q1 25 | 1.3% | 57.9% | ||
| Q4 24 | 7.0% | 58.9% | ||
| Q3 24 | 2.0% | 39.3% | ||
| Q2 24 | 23.4% | 23.0% | ||
| Q1 24 | 1.0% | 64.3% |
| Q4 25 | 0.9% | 0.3% | ||
| Q3 25 | 0.9% | 0.9% | ||
| Q2 25 | 0.7% | 0.5% | ||
| Q1 25 | 0.6% | 0.4% | ||
| Q4 24 | 0.8% | 1.0% | ||
| Q3 24 | 0.4% | 0.5% | ||
| Q2 24 | 0.8% | 1.1% | ||
| Q1 24 | 0.6% | 1.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | 2.92× | 0.84× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | 2.23× | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
